Any current/future new fundraising through debt or equity?

No new long-term borrowings are planned for the near future. The company expects to fund its CAPEX internally without raising new debt. Some short-term loans for working capital may fluctuate, but no major increase in debt expected. Debt to equity ratio is currently comfortable at about 25%. Management aims to reduce short-term loans as working capital requirements normalize. No mention of any planned equity fundraising in the call.

Any current/future capex/capital investment/strategic investment?

For FY23, the planned CAPEX is around Rs. 60-70 crores. Major portion allocated for Ahmedabad plant redevelopment. Additional CAPEX for pharma intermediates expansion and moving PAP (para-aminophenol) production to continuous processing. The continuous process at PAP will require further CAPEX as part of scaling up production. The pharma intermediates project has incurred about Rs. 55 crores out of a Rs. 60 crore budget but is not yet commercialized. OAP (ortho-aminophenol) project, with a budget around Rs. 30 crores, is also in progress but not yet commercialized. Continuous proce

Future growth expectations in sales/revenue/volumes?

FY23 volume expected around 60,000-65,000 tons, up from ~50,000 tons (Page 14-15). Hydrogenation volumes (including PAP and OAP) to increase, with PAP ramping from 300 to 500 tons/month in H1 FY23 and targeted 1000 tons/month by end of FY23 (Pages 14, 18-19). Continuous process at PAP expected to improve margins and volumes further beyond 500 tons/month (Page 19). Sales guidance: FY23 standalone revenue target ~1200-1250 crores; FY24 target ~1400 crores (Page 18). EBITDA margin expected to improve to around 15% at 500 tons/month PAP volume and higher with continuous process (Page 19).

Future growth expectations in earnings/operating earnings/profits/EPS?

Expecting revenue growth of around 35-40% for FY23 and 15-20% growth for FY24 on a standalone basis. Projected volumes: 1200-1250 tons in FY23 and approximately 1400 tons in FY24. EBITDA margin guidance around 15-16% achievable at 500-600 tons/month PAP volume, improving further with continuous processing. Anticipated gross margin stabilization near 30%, with EBITDA margin around 20-22% on a normalized basis post market stabilization. Operating efficiency expected to improve with full scaling of PAP production and commencement of continuous processing. CAPEX of Rs. 60-70 crores planned for FY2

Valiant Organics LtdQ4 FY22Chemicals & Petrochemicals

Valiant Organics Ltd Q4 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹410P/E: 23.7Market Cap: ₹1.2K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

FY23 volume expected around 60,000-65,000 tons, up from ~50,000 tons (Page 14-15).
Hydrogenation volumes (including PAP and OAP) to increase, with PAP ramping from 300 to 500 tons/month in H1 FY23 and targeted 1000 tons/month by end of FY23 (Pages 14, 18-19).
Continuous process at PAP expected to improve margins and volumes further beyond 500 tons/month (Page 19).
Sales guidance: FY23 standalone revenue target ~1200-1250 crores; FY24 target ~1400 crores (Page 18).
EBITDA margin expected to improve to around 15% at 500 tons/month PAP volume and higher with continuous process (Page 19).
Revenue growth guidance: 35-40% growth next year (FY23), followed by 15-20% growth in the subsequent year (Page 18).
New products OAP and pharma intermediates expected to start contributing from Q2 FY23, supporting volume growth (Page 8).

Margin guidance

Category 1

Expecting revenue growth of around 35-40% for FY23 and 15-20% growth for FY24 on a standalone basis.
Projected volumes: 1200-1250 tons in FY23 and approximately 1400 tons in FY24.
EBITDA margin guidance around 15-16% achievable at 500-600 tons/month PAP volume, improving further with continuous processing.
Anticipated gross margin stabilization near 30%, with EBITDA margin around 20-22% on a normalized basis post market stabilization.
Operating efficiency expected to improve with full scaling of PAP production and commencement of continuous processing.
CAPEX of Rs. 60-70 crores planned for FY23 aimed at Ahmedabad redevelopment, pharma intermediates, and PAP continuous process expansion.
Long-term debt expected to reduce from Rs. 128 crores to around Rs. 90-95 crores by end of next year, improving financial stability.

See what Valiant Organics Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

No new long-term borrowings are planned for the near future.
The company expects to fund its CAPEX internally without raising new debt.
Some short-term loans for working capital may fluctuate, but no major increase in debt expected.
Debt to equity ratio is currently comfortable at about 25%.
Management aims to reduce short-term loans as working capital requirements normalize.
No mention of any planned equity fundraising in the call.

Order book

The provided pages of the Valient Organics Limited earnings call transcript do not mention any details about the current or expected order book or pending orders. The discussion mainly focuses on production volumes, margins, CAPEX, debt, and operational efficiencies. Therefore, no specific information regarding order book or pending orders is available in the provided document excerpt. If you would like, I can assist you in locating that information if provided in other parts of the document.

See what Valiant Organics Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

For FY23, the planned CAPEX is around Rs. 60-70 crores.
Major portion allocated for Ahmedabad plant redevelopment.
Additional CAPEX for pharma intermediates expansion and moving PAP (para-aminophenol) production to continuous processing.
The continuous process at PAP will require further CAPEX as part of scaling up production.
The pharma intermediates project has incurred about Rs. 55 crores out of a Rs. 60 crore budget but is not yet commercialized.
OAP (ortho-aminophenol) project, with a budget around Rs. 30 crores, is also in progress but not yet commercialized.
Continuous process for PAP aims to increase production capacity beyond the current batch process limit of 500 tons/month.
No major new large ticket investments are planned until stabilization of ongoing projects.

Track Valiant Organics Ltd — get its next earnings analysis in your feed

How does Valiant Organics Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisValiant Organics Ltd

Rev 3Mar 1

See where Valiant Organics Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Valiant Organics Ltd rank in Chemicals & Petrochemicals?

Compare Valiant Organics Ltd against every Chemicals & Petrochemicals company (Q4 FY22) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Valiant Organics Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key investor presentation takeaways from Fine
Chemfab Alkalis Ltd (Q4 FY26)
Chlor Alkali segment: ₹55.63 crore (down 1.21% YoY from ₹56.31 crore) . Key investor presentation takeaways from Chemfab Alkalis Ltd's Q4 FY26 investor presenta
Chemfab Alkalis Ltd (Q1 FY27)
Consolidated Q1FY27 Revenue from Operations:** ₹73.16 crore, down 20.08% YoY (from ₹91.54 crore in Q1FY26). Key investor presentation takeaways from Chemfab Alk
Himadri Speciality Chemical Ltd (Q3 FY24)
1,052.51 Cr, up 1.46% YoY from Rs. Key investor presentation takeaways from Himadri Speciality Chemical Ltd's Q3 FY24 investor presentation — and how it ranks a

Compare:vs Solar Industries India Ltd vs Pidilite Industries Ltd vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →